Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study

Date 28 June 2017
Event ESMO World Congress on Gastrointestinal Cancer 2017
Session ESMO World Congress on Gastrointestinal Cancer 2017
Topics Gastrointestinal Cancers
Hepatobiliary Cancers
Immunotherapy
Therapy
Presenter Johanna Bendell
Citation Annals of Oncology (2017) 28 (suppl_3): iii137-iii149. 10.1093/annonc/mdx262
Authors J. Bendell, R. Herbst, G. Mi, J. Jin, J. Rege, D. Ferry, I. Chau
  • /

Abstract

Angiogenesis and immunosuppression are implicated in the pathogenesis and progression of invasive biliary tract cancers, including adenocarcinomas of the gallbladder, intra- and extra- hepatic cholangiocarcinoma, and Ampulla of Vater. Beyond first-line gemcitabine-cisplatin chemotherapy there is no established standard of care following progression. This is the first study to combine ramucirumab (anti-VEGFR-2) with pembrolizumab (anti-PD-1) to simultaneously target angiogenesis and immunosuppression in the tumor microenvironment.